Brief: Regeneron Pharmaceuticals Said Single Administration Of CIDEB(siRNA) Led To Reductions In Liver Fat Up To 80% That Were Sustained Through 36 Weeks
BRIEF-Regeneron Pharmaceuticals Said Single Administration Of CIDEB(siRNA) Led To Reductions In Liver Fat Up To 80% That Were Sustained Through 36 Weeks Nov 8 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
REGENERON PHARMACEUTICALS, INC.: SINGLE ADMINISTRATION OF CIDEB(SIRNA) LED TO REDUCTIONS IN LIVER FAT UP TO 80% THAT WERE SUSTAINED THROUGH 36 WEEKS
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsCorrected: UPDATE 2-US FDA approves Regeneron's drug for generalized myasthenia gravis (November 18)
Refile: US FDA approves Regeneron's drug for generalized myasthenia gravis
Brief: Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing
US FDA approves Sanofi's genetic disorder drug
Brief: Regeneron Pharmaceuticals Said Single Administration Of CIDEB(siRNA) Led To Reductions In Liver Fat Up To 80% That Were Sustained Through 36 Weeks